Press releases

Year: All
  • All

2021




2020


December 18, 2020 Regulatory
IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000


December 8, 2020
IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam


November 4, 2020
IRLAB starts Phase IIb/III study with mesdopetam in the US


October 30, 2020 Regulatory
Nomination committee in IRLAB appointed ahead of annual general meeting 2021


October 1, 2020 Regulatory
IRLAB’s mesdopetam IND accepted by the US FDA


September 30, 2020
IRLAB’s shares are now traded on Nasdaq Stockholm Main Market


September 25, 2020 Regulatory
IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market


September 23, 2020 Regulatory
IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market


September 10, 2020
IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET


August 3, 2020
IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO


July 9, 2020
IRLAB’s clinical drug candidate IRL752 published in JPET


June 24, 2020
IRLAB’s mesdopetam featured on cover of top-tier publication JPET


June 4, 2020
IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON


May 7, 2020 Regulatory
Report from the Annual General Meeting of IRLAB Therapeutics AB


May 6, 2020
IRLAB’s clinical drug candidate mesdopetam published in JPET


April 7, 2020 Regulatory
IRLAB publishes the annual report for 2019


March 23, 2020
IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders


February 27, 2020
IRLAB’s rights issue oversubscribed


February 7, 2020 Regulatory
IRLAB publishes prospectus relating to the rights issue


February 4, 2020
IRLAB’s IRL790 receives new name ‘mesdopetam’




2019


December 12, 2019 Regulatory
IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million


December 12, 2019 Regulatory
IRLAB intends to make a capital raise of approximately SEK 215 million


November 6, 2019
IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe


October 21, 2019
IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference


October 17, 2019 Regulatory
Nomination committee in IRLAB appointed


September 26, 2019
IRLAB’s IRL790 is proposed a unique INN by WHO


September 23, 2019
IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders


August 28, 2019
IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results


July 15, 2019 Regulatory
IRLAB reports top line results from Phase IIa study with IRL790


May 28, 2019
IRLAB and research consortium awarded MSEK 2.9 Vinnova grant


May 27, 2019
Today, May 27, is the last day of trading in IRLAB’s share before share split


May 17, 2019 Regulatory
IRLAB announces share split


May 9, 2019
IRLAB completes recruitment for its Phase II study with IRL790 in Parkinson’s disease patients with dyskinesia


April 25, 2019 Regulatory
IRLAB – Resolutions at Annual General Meeting 2019


April 3, 2019 Regulatory
IRLAB Therapeutics AB publishes annual report for 2018


March 14, 2019
IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review




2018


December 18, 2018
IRLAB provides update on drug candidate IRL790’s clinical program


December 6, 2018
Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790


November 22, 2018
A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO


October 30, 2018
IRLAB provides in-depth information on results from successful Phase IIa study with IRL752 in Parkinson’s disease


September 26, 2018
IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston


September 20, 2018 Regulatory
Nomination committee appointed in IRLAB


September 19, 2018 Regulatory
IRLAB nominates two new candidate drugs and updates the pipeline


September 11, 2018
IRLAB Receives Notice of Allowance for U.S. Patent


August 30, 2018
IRLAB reports promising efficacy data from Phase IIa-study with IRL752


August 30, 2018 Regulatory
IRLAB reports promising efficacy data from Phase IIa-study with IRL752


August 29, 2018
IRLAB report for Q2 2018


June 29, 2018 Regulatory
IRLAB reports top-line results from Phase IIa study with IRL752


May 23, 2018 Regulatory
IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden


May 17, 2018 Regulatory
IRLAB prepares for listing on the Nasdaq Stockholm main market


May 16, 2018 Regulatory
IRLAB – Resolutions at Annual General Meeting 2018


April 13, 2018
Summoning to Annual General Meeting


March 12, 2018
International attention on IRLAB’s discovery program


March 12, 2018
International attention on IRLAB’s discovery platform


February 23, 2018
IRLAB featured in SwedenBIO press release


January 31, 2018
IRLAB update on clinical Phase II pipeline – IRL752 and IRL790




2017


November 15, 2017 Regulatory
IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain


October 5, 2017 Regulatory
IRLAB receives approval from the Finnish MPA (Fimea)


October 4, 2017
IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia


September 20, 2017 Regulatory
Nomination committee appointed in IRLAB


August 25, 2017 Regulatory
IRLAB receives approval to initiate Phase II trials with IRL752


August 17, 2017 Regulatory
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790


May 16, 2017 Regulatory
IRLAB Therapeutics delårsrapport jan-mars 2017


May 15, 2017
IRLAB announces positive results from Phase Ib study with IRL790


April 24, 2017
IRLAB strengthens Board of Directors with leading competences


April 10, 2017
Annual Report for 2016 published


April 10, 2017
IRLAB Therapeutics AB summons its shareholders to the Annual General Meeting in Gothenburg on May 16, 2017


April 10, 2017 Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning för 2016


March 16, 2017
IRLAB therapeutics AB reports topline results from its Phase I SAD and MAD study with IRL752 and enters into an agreement with Clinical Trial Consultants (CTC) for the planned Phase II study in Parkinson disease dementia.


February 28, 2017
First day of trading of shares for IRLAB Therapeutics AB (publ.) at Nasdaq First North Premier


February 27, 2017 Regulatory
IRLAB Therapeutics AB (publ) Bokslutskommuniké för 2016


February 14, 2017
IRLAB Therapeutics announces outcome of new share issue – first day of trade planned for February 28th


January 24, 2017
IRL’s drug discovery platform, the Integrative Screening Process (ISP), and an application, has been published in ACS Chemical Neuroscience




2016




2015




2014